Showing results (1-10 of 189) with videos related to
Sort By:
Pageof 19
Expert Review of Anti-Infective Therapy|November 22, 2013
Antiretroviral therapy and tuberculosis: does the regimen matter?Frank van Leth, Ferdinand W N M Wit, Sabine M HermansTropical Medicine & International Health : TM & IH|November 8, 2012
Unrecognised tuberculosis at antiretroviral therapy initiation is associated with lower CD4+ T cell recoverySabine M Hermans, Frank van Leth, Agnes N Kiragga, et al.Antiviral Therapy|February 21, 2013
Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weightingSabine M Hermans, Yukari C Manabe, Agnes N Kiragga, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|March 1, 2005
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudyFrank van Leth, Casper B Huisamen, Roberto Badaro, et al.Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 20, 2022
Unbiased antimicrobial resistance prevalence estimates through population-based surveillanceFrank van Leth, Constance SchultszInfectious Diseases (London, England)|December 3, 2016
Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic reviewWassilis Sc Bruins, Frank van LethBMC Public Health|September 3, 2016
Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method designKirsten Evenblij, Annelies Verbon, Frank van LethMedicine|August 9, 2019
Longitudinal virological outcomes and factors associated with virological failure in behaviorally HIV-infected young adults on combination antiretroviral treatment in the Netherlands, 2000 to 2015Annouschka M Weijsenfeld, Charlotte Blokhuis, Martijn M Stuiver, et al.AIDS (London, England)|July 11, 2023
No evidence of rapid reversibility of tenofovir alafenamide and/or integrase strand transfer inhibitor-associated weight gainMyrthe L Verburgh, Ferdinand W N M Wit, Anders Boyd, et al.The Journal of Infectious Diseases|June 29, 2002
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapyFerdinand W N M Wit, Gerrit Jan Weverling, Jan Weel, et al.Pageof 19